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Summary Estraumustine phosphate (EMP), a cytotoxic drug used in the treatment of prostatic carcinoma,
has been shown to exert cytotoxic effects on glioma cells in vitro. The drug uptake is assumed to depend on a
specific estramustine binding protein (EMBP). One of the main difficulties in achieving cytotoxic effect in
malignant brain tumours is believed to be due to the poor penetration of cytotoxic drugs into tumour tissue.
In patients with malignant supratentorial brain tumours we have analysed the uptake of EMP metabolites in
tumour tissue after oral administration and demonstrated EMBP in the same tissue specimens. Sixteen patients
were given 280 mg EMP orally 14 h prior to surgery. Specimens from brain tumour tissue, cystic fluid, and
serum were collected during surgery. Using gas chromatography the metabolites of EMP, estramustine (EaM)
and estromustine (EoM), were quantified, EMBP was demonstrated by immunohistochemistry. The mean
concentrations of EaM and EoM, expressed in ng g-', were 60.3 and 38.4 in tumour tissue and 3.5 and 56.3 in
serum, respectively. An accumulation of EaM in tumour tissue was found with a mean concentration gradient
of 16.1 versus serum, while the gradient for EoM was 0.76. EMBP was demonstrated with a high degree of
staining in all but one tumour. The high concentrations of EaM and EoM found in malignant brain tumour
tissue correspond to potentially cytotoxic levels. The present results as well as the earlier in vitro demonstrated
cytotoxic effects on glioma cells strengthen the possibility of a therapeutic effect of EMP in the treatment of
malignant brain tumours.
Estramustine phosphate (EMP), an ester of 17p-
estradiolphosphate and nornitrogen mustard, is a cytotoxic
drug used in the treatment of advanced prostatic carcinoma.
Recently, it has been shown that EMP also exerts cytotoxic
effects on several human glioma cell lines (von Schoultz et
al., 1989). A significant uptake and metabolism of EMP as
well as retention of its main metabolites in glioma cells were
also demonstrated (von Schoultz et al., 1989) as previously
has been observed in prostatic tumour cells (Kruse et al.,
1988b). The anti-tumouros activity seems, at least partially,
to be coupled to the presence of a specific estramustine
binding protein (EMBP) in the prostatic tumour cells (Fliich-
ter et al., 1989; Bjork et al., 1985). By using various techni-
ques including immunohistochemistry and radioimmuno-
assay, EMBP has also been demonstrated in glioma cells in
vitro and in specimens from human brain tumour tissue (von
Schoultz et al., 1988; von Schoultz et al., 1991). It has been
suggested that EMBP did take part in the accumulation of
the active metabolites estramustine (EaM) and estromustine
(EoM) in prostatic carcinoma cells (Bjork et al., 1985; Norlen
et al., 1988; Kruse et al., 1988a) and in malignant glioma
cells (von Schoultz et al., 1988; von Schoultz et al., 1989). In
the present study, the uptake and metabolism of EMP in
patients with malignant brain tumours have been analysed
and concomitantly, the occurrence of EMBP in the same
tissues has been demonstrated.
Patients and methods
Patients
Sixteen consecutive patients with intracerebral supratentorial
tumours operated at the Department of Neurosurgery were
included in the study. The mean age was 56.1 years (range
23-79) and the male/female ratio was 9/7. The patients were
given 280mg EMP orally 12-14h before surgery. This time
was chosen with knowledge of earlier pharmacokinetic
studies to allow detection of an eventual drug retention in the
tumor tissue (Gunnarsson et al., 1984). The given dose is
routinely used in prostatic carcinoma patients. All patients
received routinely 8 mg betamethason intravenously 12 and
2 h before surgery. Nine patients had been treated with
betamethason at most for one week before surgery due to
severe cerbral edema. Prophylactic antacid medication consis-
ting of magnesium and aluminium hydroxide was given to
five of the patients with earlier dyspepsia or ventricular
ulcera. Exclusion criteries for the study included cardiac
failure, angina pectoris, and impaired liver and renal func-
tion. The study was approved by the local ethics committee
and informed consent was obtained individually from all
patients.
Surgery
At surgery, specimens of tumour tissue were collected and
venous blood samples were taken for analysis of EaM and
EoM. The interval between administration of EMP and sam-
ple taking was approximately 12-14h. In some patients it
was possible to collect cystic fluid from tumour. Specimens
for analysis were removed with precaution in order to avoid
denaturation. The samples were immediately frozen and
stored at -70'C until analysed. Additional tissue samples
were also taken for histopathological routine examination
and immunohistochemical staining for EMBP.
Analysis ofEMP metabolites, EaM and EoM
EMP metabolites were measured in tumour specimens,
serum, CSF, and cystic fluid, EaM and EoM were analysed
using gas chromatography according to a method earlier
described (Andersson et al., 1981; Andersson et al., 1982).
The method was further modified for analysing tissue speci-
mens. Tissue samples were homogenised with 15 volumes of
methanol. Briefly, the extracts were evaporated and the
residues dissolved in 10 ml of water, extracted with hexane
and separated on an aluminumoxide column. The samples
were dissolved in xylene and quantified by gas chromatog-
raphy with NP detection (HP 5890, Hewlett Packard).
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Immunohistochemistry
The presence of EMBP in the tumour tissue was assessed by
the indirect antibody peroxidase technique on paraffin
embedded material (Sternberger, 1979; Hsu et al., 1981; von
Schoultz et al., 1988). Endogenous peroxidase activity was
blocked by addition of H202 in methanol. A primary mouse
monoclonal antibody (Mab EMBP-1) (Kabi-Pharmacia AB,
Helsingborg, Sweden) raised against purified rat EMBP was
added diluted 1/10 to the sections for 1/2-1 h. The antibody
had a demonstrated cross reactivity to human EMBP (Bergh
et al., 1988). Rabbit anti-mouse avidin-biotin peroxidase-
antiperoxidase complexes (Vectastain, Burlingame, CA,
USA) were added after sequential washings in PBS. The
staining reaction was developed in DMSO/ethylcarbazole,
followed by counterstaining with haemathoxylin and moun-
ting in glycerol-gelatin. All tumours were also processed the
same way as above, but without addition of monoclonal
antibody in order to serve as negative control. Additionally,
one small lung cancer cell line, U-1285, and prostatic tissue
were used as negative and positive control respectively. The
immunohistochemical staining was evaluated by counting the
proportion of cells positively stained for EMBP and semi-
quantitatively estimating the intensity of staining defined as
missing (0), low (1), moderate (2), and high (3).
Statistical analysis
Statistical analysis were performed with one factor ANOVA,
linear regression, and Mann-Whitney U-test using Stat-View
512 + statistical program for Macintosh computer.
Results
The metabolites of EMP, EaM (estramustine) and EoM (est-
romustine), were demonstrated in both serum and brain
tumours with the technique described. The patients, their
diagnosis, and the concentrations of EaM and EoM together
with the results of immunohistochemical staining of EMBP
are summarised in Table I.
Fourteen of the 16 patients suffered from primary intra-
cerebral tumours (nine astrocytoma grade III, two astro-
cytoma III-IV, one glioblastoma, one ependymoma III, and
one hemangioreticuloma). Two patients had metastasis (one
melanoma and one thyroid cancer).
The concentrations of EaM and EoM in tumour tissues
and in serum showed a great variability. In one patient (no 1,
Table I) no drug could be detected in serum nor in tumour
tissue. Retrospectively it was assumed that his patient never
ingested the EMP, and hence he was excluded from further
analysis. In the other patients, relatively high levels of EaM
and/or EoM were detected in serum as well as in tumour
tissue. Linear regression showed a high correlation between
the levels of EaM and EoM both in serum and in tumour
tissue (P<0.01; P<0.001). The most striking feature was
the high EaM level in tumour tissues relative to serum,
indicating a retention of EaM in tumour tissue. A com-
parison between patients with astrocytoma and patients with
other brain tumours did not show any statistical difference in
any of the measured drug concentrations, neither in serum
nor in tumour tissue.
The mean values and range of EaM and EoM concentra-
tions in serum and tumour tissue in patients with astro-
cytoma, and in the same patients divided into different
groups according to their preoperative medication, are pres-
ented in Table II. In patients receiving both steroids and
antacids (no. 1,8,11,12,15), the concentrations of EaM and
EoM in serum, as well as the accumulation of EaM in
tumour tissues were generally lower than in patients receiving
only steroids (no. 3,4,6,10,13,16). Patients with astrocytoma
receiving both steroids and antacids had in fact no detectable
levels of EoM in the tumours.
Analysis of cystic fluid was done in six patients (Table I).
In five of them the levels of EaM and EoM were generally
lower in cystic fluid than in tumour tissue and serum, or even
not detectable. In one patient the level of EaM in cystic fluid
was approximately the same as in tumour tissue and slightly
higher than in serum (no. 6).
The results of immunohistochemical staining for EMBP
are shown in Table I. The staining for EMBP was highly
positive for all the tumours except for the metastasis from a
thyroid cancer. There was no correlation between the concen-
trations of EaM and EoM measured and the degree of
staining for EMBP (ANOVA and linear regression).
Discussion
In the present study the main metabolites of EMP, EaM
(estramustine) and EoM (estromustine), were detected in high
concentrations in brain tumour tissue from patients given
EMP 14 h prior to surgery. There was generally a high
Table I Uptake of estramustine (EaM) and estromustine (EoM) in human brain tumor tissue, serum, and cystic fluid. Immunohistochemical
staining of tumor tissue. Mean values, S.D., median, and range are given excluding patient no. 1
Concentration (ngg-')
Pat. diagnos Tumour Serum Tumour/serum Cystic fluid EMBP staining
EoM EaM EoM EaM EoM EaM EoM EaM Cells % Intensity
1 astro III nd nd nd nd - nd nd 70 2
2 hemangioret. 31 nd 54 nd 0.57 70 2-3
3 astro III nd 13 5 nd - - nd nd 80 2-3
4 astro III 90 138 153 10 0.59 13.8 80 1-2
5 melanoma 89 59 102 4 0.87 14.8 70 2
6 astro III-IV 11 13 12 2 0.92 6.5 7 14 80 1
7 glioblast. nd 26 9 nd - - nd 2 70 1-2
8 astro III nd 125 104 6 - 20.8 2 2 70 1
9 thyr.ca. 160 125 104 6 1.54 20.8 35 4 5 1 10 astro III 8 50 19 2 0.42 25 25 1-2
11 astro III nd 15 26 2 - 7.5 50 2
12 astro III nd nd 4 nd - - 80 2
13 astro III 16 86 43 4 0.37 21.5 80 1 14 ependym. III 156 132 126 9 1.24 14.7 90 2-3
15 astro III nd 52 35 3 - 17.3 60 1-2
16 astro III-IV 15 70 49 5 0.31 14 70 1
mean 38.4 60.3 56.3 3.5 0.76 16.1
S.D. 56.9 50.3 48.9 3.2 0.42 5.8
median 11.0 52.0 43.0 3.0 0.59 14.9
range 0-160 0-138 4-153 0-10 0.31-1.54 6.5-25
nd = not detectable360 A.T. BERGENHEIM et al.
Table II The mean uptake in ng g' and accumulation of estromustine (EoM) and estramustine (EaM) in 11 patients with
astrocytoma III-IV receiving steroid treatment with or without additional antacida prior to surgery
Group n Tumour Serum Tumour/serum
EoM EaM EoM EaM EoM EaM
All astro III-IV 11 12.7 (0-90) 51.1 (0-138) 40.9 (0-153) 3.1 (0-10) 0.52 (0.01-0.92) 15.88 (0-25)
Steroids + antacida 5 0 38.4 (0-125) 33.8 (0-104) 2.2 (0-6) 0 15.17 (0-21)
Steroids 6 23.3 (0-90) 61.7 (13-138) 46.8 (5-153) 3.83 (0-10) 0.52 (0-0.92) 16.16 (6.5-25)
tumour/serum concentration ratio, especially for EaM,
indicating an accumulation of this metabolite in the tumour
tissue. The concentrations of EaM and EoM in serum were
comparable to those reported in an earlier study on patients
with prostatic carcinoma treated with higher doses of EMP
(Gunnarsson et al., 1984). In those patients, an oral dose of
420 mg EMP was given and after 14 h the plasma concentra-
tion of EoM was approximately 100 ngml-l and that of
EaM was l0ngml-1 or lower.
In this study, the concentration of EaM in the tumour
tissue exceeded the serum concentration in all patients where
EaM could be detected. The mean tumour/serum ratio was
16.1 (range 6.5-25). In contrast, EoM levels were low in
tumour tissue compared to serum (mean ratio 0.76, range
0.31-1.54). Most interestingly, the ratio of EaM in brain
tumour tissue exceeded the concentration ratio achieved in
patients with prostatic carcinoma, while the EoM ratio was
at comparable level (Bjork et al., 1985). It must be
emphasised that the doses used in the studies on prostatic
carcinoma were at least twice those we used in the present
study, i.e. 2 x 560mg/day or 2 x 840mg/day (Bjork et al.,
1985) or 420 mg as a single dose (Gunnarsson et al., 1984).
Thus, although the encountered concentrations are not
directly comparable, the results clearly indicate that the
accumulation in brain tumour tissues was at least as high as
in prostatic carcinoma.
In the treatment of gliomas the poor effect of many
cytotoxic drugs is strongly assumed to be caused by a poor
uptake in tumour tissue due to the blood-brain (or blood-
tumour) barrier. A recently presented study did show an
uptake of TCNU (tauromustine) in glioma tissue, however,
with a lower concentration in tumour tissue than in serum
(Whittle et al., 1990). Another study demonstrated that the
uptake of doxorubicin in brain tumour tissue was far below
the cytotoxic level for the drug (von Holst et al., 1990). This
insufficient uptake probably explains the lack ofclinical effect
of this drug as well as other antitumoural agents in the
treatment of brain tumours. Therefore, our finding of a high
concentration of the cytotoxic metabolites of EMP in tumour
tissue could indicate the possibility for a clinical effect of
EMP in the treatment of glioma.
Whether the higher concentration of EaM in brain tumour
tissue was due to an active uptake and accumulation and/or
to a subsequent retention is unclear. During the first 6-8 h
following intake of EMP in patients with prostatic carcinoma
the concentration of EaM in serum was higher than after
14 h (Gunnarsson et al., 1984) and at a comparable level to
the concentration of EaM found in brain-tumour tissue after
14 h in the present study. The concentration of EoM in
serum, on the other hand, did not decline with time as fast as
the concentration of EaM and was still at a high level even
after 14 h. In spite of this, the concentration of EoM in
tumour tissue was lower than in serum for most patients. The
high levels of EaM in tumour tissue could also possibly be
explained by metabolism. In glioma cell cultures, metabolism
of EMP has been shown with apparently EaM as the main
metabolite (von Schoultz et al., 1989). However, after oral
administration of EMP, detectable levels of EMP in serum
have not been demonstrated, probably due to a first-pass
metabolism (Gunnarsson et al., 1984), and thus, it is difficult
to compare these results with the in vitro situation where the
cultured cells have been exposed to EMP directly. Never-
theless, the in vitro situation has also shown a cytotoxic effect
of EaM itself on prostatic carcinoma cells and malignant
glioma cells at comparable concentrations (Hartley-Asp,
1984; von Schoultz et al., 1989; von Schoultz et al., 1990).
There was a considerable variation in plasma and tumour-
tissue concentration encountered among the different
patients. This could possibly depend on differences in the
disturbance of the blood brain barrier in the different
tumours. However, there was a high correlation between the
concentrations in serum and tumour tissue which would
rather suggest differences in the absorption from the gastro-
intestinal tract. Most importantly, we found that patients
with antacid treatment had lower uptake both in serum and
in tumour-tissue. Thus it seems that antacids hamper the
drug absorption. It has recently been shown that absorption
and plasma concentration also are largely influenced by food
constitutents, and especially milk containing products (Gun-
narsson et al., 1990). Thus, it is of clinical importance to
consider the use of concomitant drugs and intake of milk-
containing food.
The immunohistochemical staining for EMBP, in the pres-
ent study, showed a high occurrence of EMBP in all astro-
cytoma patients as shown in an earlier study (von Schoultz et
al., 1991). EMBP has been shown to have high affinity
binding properties to both EaM and EoM (Forsgren et al.,
1979a,b) and the anti-tumouros effect of EMP has been
suggested to be dependent on the presence of this protein
(Bjork et al., 1985; Fliichter et al., 1989). Thus, EMBP may
play a crucial role in enhancing the cytotoxic action by
causing accumulation of especially EaM. The relatively low
concentrations of EaM/EoM in the cystic fluid of the
tumours compared to the solid tissue component may further
indicate the importance of EMBP in the retention of the
active metabolites of EMP. On the other hand, in one patient
with metastasis from a thyroid carcinoma the staining for
EMBP was weak but high levels of EaM and EoM were
detected in tumour tissue. This may reflect a high EMBP
binding affinity in all tumours for EaM and EoM. However,
the exact nature and role of EMBP in brain tumour tissue is
so far unknown. The calf brain is shown to have high
concentrations of the so called microtubule-associated pro-
tein (MAP-2) (Vallee et al., 1982; Caceres et al., 1984). This
protein is known to have binding affinity for estramustine
and its binding has been suggested to inhibit brain micro-
tubule assembly in vitro (Friden et al., 1987; Steams & Tew,
1988). Thus, it could be a possibility that EMBP and MAP-2
have common antigenic properties which actually could mean
that the EMBP immunohistochemically detected could in fact
be MAP-2. Future studies will evaluate this.
In conclusion, the present study demonstrates a high
uptake and retention of the metabolites of orally
administered EMP in human brain tumour tissue with a high
concentration ratio (tumour vs serum) especially for the
metabolite EaM. Hence, it seems that the blood-brain barrier
did not hamper the passage of EMP and/or its metabolites.
The presence of EMBP in brain tumour tissue was demon-
strated and its importance in retaining the metabolites of
EMP was further postulated. These observations may have
direct clinical implications, and certainly justify a clinical
evaluation of EMP in the treatment of patients with malig-
nant brain tumours.
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